Graft failure (GF) is a significant complication after allogeneic hematopoietic stem cell transplantation (HCT) and is associated with a high mortality rate. We performed re-transplantation using haploidentical-related donors to rescue children with early GF. Between 2008 and 2013, 10 patients received re-transplantation from haploidentical family donors. The median age at HCT was 13.5 years and the median time between transplantations was 52.5 days. Conditioning regimen with fludarabine and CY was used in seven patients, and TBI was added in three patients. All 10 patients received T-cell-depleted grafts using CD3 or CD3/CD19 MoAb. The median numbers of CD34 þ and CD3 þ cells were 5.52 Â 10 6 /kg and 1.08 Â 10 6 /kg, respectively. For GVHD prophylaxis, mycophenolate mofetil (MMF) and tacrolimus or MMF and CYA were used. All 10 patients achieved a sustained neutrophil engraftment and maintained a complete donor chimerism at the time of analysis (median 23 months, range 6-62 months). Nine of 10 patients were alive, and one patient with moyamoya disease with AML died of encephalopathy 7 months post transplant. This study suggests that fludarabine-and CY-based conditioning with T-cell-depleted haploidentical HCT is a feasible option to rescue pediatric patients with primary GF. Keywords: pediatric; graft failure; haploidentical hematopoietic stem cell transplantation INTRODUCTION Graft failure (GF) after allogeneic hematopoietic stem cell transplantation (HCT) is associated with a high mortality. The overall frequency of GF under myeloablative conditioning has been reported to be o5%. Meanwhile, it reaches around 10% for haploidentical HCT (HHCT) and umbilical cord blood transplantation (UCBT).
INTRODUCTION
Graft failure (GF) after allogeneic hematopoietic stem cell transplantation (HCT) is associated with a high mortality. The overall frequency of GF under myeloablative conditioning has been reported to be o5%. Meanwhile, it reaches around 10% for haploidentical HCT (HHCT) and umbilical cord blood transplantation (UCBT). [1] [2] [3] Following GF, a second transplantation offers the best opportunity for long-term, disease-free survival for these patients. However, the best conditioning regimen and the optimal stem cell source for salvage transplantation are yet to be determined, and achieving stable engraftment is often difficult with engraftment rates as low as 30%. 4 Waki et al. 5 reported the results of salvage UCBT. Although more than half of the patients achieved neutrophil engraftment, transplant-related mortality (TRM) at day 100 was 45, and 60% of the deaths were related to infectious complications, with the probability of 1-year OS at 33%. On the other hand, second transplantation using haploidenticalrelated donors showed more favorable results. 6, 7 We performed salvage transplantation using T-cell-depleted grafts from haploidentical-related donors to rescue children and adolescents with early GF after initial transplantation, and in this study, we report the results.
PATIENTS AND METHODS
This retrospective study comprised 10 pediatric patients who received a second transplantation for GF using haploidentical-related donors at Asan Medical Center. From May 2008 to February 2013, 10 patients with GF underwent HHCT. The detailed characteristics of patients and the first and second transplantations are presented in Tables 1 and 2 . Primary diagnoses included myelodysplastic syndrome (n ¼ 1), severe aplastic anemia (n ¼ 6), and AML; n ¼ 3). Of three patients with AML, two were in the first CR and one had persistent disease at the time of first transplantation. No patient had significant infections or comorbidities at the time of first transplantation. After first transplantation, three patients developed CMV antigenemia that was treated with pre-emptive ganciclovir and cleared up at the time of second transplantation.
Median age at the time of the second transplantation was 13.5 years (range 1.0-21.9 years), and median interval from the failed transplantation to salvage transplantation was 52.5 days (range 28-89 days). Previous transplantations were T-cell-depleted HHCT (n ¼ 7), T-cell-replete HHCT (n ¼ 1) and UCBT (n ¼ 2).
Conditioning regimens were non-TBI, fludarabine-based regimen in seven patients and TBI-based regimen in three patients. Non-TBI regimen comprised fludarabine (150 mg/m 2 ) and CY (100-120 mg/kg) in six patients, and rabbit-antithymocyte globulin (rATG; 6 mg/kg) was added in one patient. TBI-based regimen comprised TBI (400-600 cGy), fludarabine (150 mg/m 2 ) and CY (100-120 mg/kg) in two patients, and rATG (6 mg/kg) was added in one patient. Mobilized PBSCs were processed for CD3 (n ¼ 8) or CD3/CD19 (n ¼ 2) depletion by negative selection using the fully automated CliniMACS device (Software Version 2.40, Miltenyi Biotec, Bergisch-Gladbach, Germany). The patients receiving CD3-depleted grafts without CD19 deletion were administered one dose of rituximab (375 mg/m /kg), respectively. For GVHD prophylaxis, mycophenolate mofetil (MMF) and tacrolimus (FK-506; n ¼ 7), or MMF and CYA (n ¼ 3) were used. All patients received broad-spectrum antibiotics and antiviral and antifungal prophylaxis. G-CSF was administered from day 5 until engraftment. Since 2011, we used an intensive strategy of CMV prevention that consisted of ganciclovir from day À 8 to day À 1, foscarnet from day 0 to day of engraftment, and subsequent valganciclovir at least to day 100 or day on which CD4 þ cell count increased to 4100 cells/mL. 8 CMV was monitored twice a week by a pp65 antigenemia test and real-time polymerase chain reaction (PCR) analysis. Pre-emptive therapy with ganciclovir was started if any positive result of PCR or antigenemia for CMV was obtained. Plasma EBV DNA was monitored once weekly in the first 3 months after HCT and monthly thereafter with real-time PCR analysis.
BM examination was performed day 28 after transplantation to assess donor-cell engraftment. Samples of peripheral blood were used to assess donor-cell chimerism at day 14, 28, 60, 90, 180 and 365 after salvage transplantation. PCR amplification and subsequent size comparison of multiple STR was used to detect recipient and donor chimerism.
GF was defined as lack of donor-cell engraftment by day 28 post transplant, or marrow hypoplasia following engraftment and loss of donor cells with or without recovery of host hematopoiesis. The day of neutrophil engraftment was defined as the first of 3 consecutive days on which the ANC exceed 500/mL. Platelet engraftment was defined as the last of 7 consecutive days on which the platelet counts exceed 20, 000/mL without transfusion. Acute GVHD was diagnosed and graded according to standard 9, 10 and treated as previously reported. 11 Children who were alive for more than 100 days after HCT with sustained donor engraftment were considered to be evaluable for chronic GVHD, which was classified according to previously reported criteria. 12 For statistical analysis, the reference date was set to 1 August 2013. The primary endpoint was the engraftment rate after second transplantation, and secondary endpoints were the probabilities of OS and EFS, and the cumulative incidence of GVHD and TRM. OS and EFS were obtained using the Kaplan-Meier method. The cumulative incidence of GVHD and TRM were evaluated using the method of Gray. Statistical analyses were performed using SPSS version 17.0 (IBM SPSS, Chicago, IL, USA) and Stata 11.0 (StataCorp, College Station, TX, USA).
RESULTS

Engraftment
Outcomes after second HHCT are presented in Table 3 . All 10 patients achieved a sustained neutrophil engraftment at median 11 days (range 9-12 days) post transplant, and all of them achieved a platelet engraftment at median 20.5 days (range 17-30 days) post transplant ( Figure 1 ). Complete donor chimerism (4 95%) was confirmed at day 28 for all patients, and full-donor chimerism was maintained at the time of analysis (median 23 months, range 6-62 months).
GVHD
Five of 10 patients experienced acute GVHD. Three patients developed grade II acute GVHD on day 11, 15 and 21, and disease was limited to the skin (stage 3 skin). Two patients developed grade III acute GVHD on day 12 and 64. One patient had stage 3 gastrointestinal GVHD, and the other had combined stage 3 skin and stage 2 gastrointestinal involvement. None developed grade IV acute GVHD. Two patients with grade III acute GVHD received a relatively large amount of CD3 þ cells (2.5 Â 10 6 /kg and 1.25 Â 10 6 /kg, respectively). All patients with acute GVHD were successfully treated with i.v. methylprednisolone (2 mg/kg/day) with concomitant tacrolimus and MMF. The cumulative incidences of acute GVHD Xgrade II and Xgrade III were 50% and 25%, respectively. Three of 10 evaluable patients developed limited skin chronic GVHD controlled by topical steroids. No patient developed extensive chronic GVHD, and there was no GVHD-related death.
Immune reconstitution T-cell and natural killer (NK) cell reconstitution data are depicted in Figure 2 . Eight of the nine evaluable patients achieved CD3
þ cell counts of 4300/mL on day 90, and seven of the eight evaluable patients achieved CD3
þ cell counts of 4400/mL on day 180. Six of the nine evaluable patients achieved CD4
þ cell counts of 4100/ mL on day 90, and all of the eight evaluable patients attained 4100/mL on day 180. CD56
þ NK cells showed an early surge in the first 2 months and a decline thereafter, and the median number of NK cells remained more than 200/mL throughout the follow-up period.
Infection
All patients were CMV IgG-positive at the time of transplantation and received stem cells from CMV IgG-positive donors. Three 
Transplant-related mortality
In all, 9 of the 10 patients survived without any significant morbidity. The one patient who died had AML evolved from myelodysplastic syndrome and progressive moyamoya disease with hemiparesis at the time of transplantation. After the second transplant, he suffered from grade II acute GVHD, limited skin chronic GVHD, CMV antigenemia and EBV DNAemia, which were successfully managed. He died of encephalopathy of an unknown cause, which was thought to be associated with his moyamoya disease, with sudden deterioration of his mental status at 7 months post transplant.
OS
Nine of 10 patients are alive at a median follow-up of 23 months (range 6-62 months). The 2-year probability of OS and EFS was 88% (Figure 3 ). Three patients with AML or myelodysplastic syndrome are alive without relapse, and six patients with severe aplastic anemia are alive without transfusion requirements.
DISCUSSION
Salvage transplantation is the best treatment option for GF, although it is hard to find a matched alternative donor over the short term, and a high infection-related mortality associated with prolonged neutropenia and damaged organ function has been a major drawback. 13 Salvage transplantation with UCB seems to be stalled by the risk of second GF and a high incidence of infectionrelated TRM. As an alternative to UCBT, second transplantation using haploidentical-related donors has received much attention. Lang et al. 7 reported successful salvage HHCT results in 11 patients with GF. They infused mega doses of CD34 þ stem cells (23.5 Â 10 6 /kg) to rescue BM, but it is sometimes too hard to harvest this number of stem cells from one donor. Recently, Yoshihara et al. 6 reported another outcome of salvage HHCT for GF. They transplanted unmanipulated PBSC using reduced intensity conditioning (RIC). With relatively small stem cell doses (4.7 Â 10 6 /kg), all eight patients successfully engrafted, although grade III-IV acute GVHD developed in four patients, and two patients died from acute GVHD.
We performed salvage HHCT with CD3-or CD3/CD19-depleted PBSC under fludarabine and CY-based conditioning. All 10 patients successfully engrafted with a relatively low stem cell dose (5.5 Â 10 6 /kg). The incidence of acute GVHD was higher than that reported by Lang et al. 7 This may reflect the higher median T-cell dose transplanted. PBSC products were T-cell depleted, but actual infused numbers of CD3 þ T cells were higher than 5 Â 10 4 / kg and all patients needed GVHD prophylaxis. Bethge et al. reported a higher incidence and degree of GVHD after CD3/CD19-depleted HHCT compared with the low incidence of o10% in CD34 þ -selected HHCT.
14 They observed one case of grade IV acute GVHD; more than 40 Â 10 4 /kg of CD3 þ T cells had been infused and they concluded that the dose of CD3 þ T cells was associated with GVHD. Another previous study suggested that a T-cell dose 48 Â 10 4 /kg was associated with a higher risk of GVHD, whereas a T-cell dose o5 Â 10 4 /kg is safe and effective for preventing GVHD without post transplant immunosuppression. 15 Our two patients with grade III acute GVHD received 2.5 Â 10 6 /kg and 1.25 Â 10 6 /kg CD3 þ cells. However, all patients received more than 5 Â 10 4 /kg CD3 þ cells and only five patients developed over grade II GVHD, and most of them were controlled with first-line treatment of corticosteroids. Relatively, low incidence of severe GVHD in our study could be attributed to T-cell depletion and extensive post transplant immunosuppression using both MMF and calcineurin inhibitors. Infused CD3 þ T-cell dose is an important risk factor for GVHD, but our results suggest that effective GVHD prophylaxis is also important in preventing progression to overt lethal GVHD. On the other hand, a higher incidence of GVHD has been reported in second transplants. 4, 16, 17 Although the incidence of chronic GVHD was not high, we observed a higher frequency of acute GVHD than that observed in the study by Ogawa et al. 18 for unmanipulated first HHCT. In their study, RIC and GVHD prophylaxis consisting of tacrolimus and methylprednisolone were used, and only five of 25 patients developed grade II acute GVHD. The reason for the increased incidence of acute GVHD after second HHCT remains unclear, although it may be associated with the kind of GVHD prophylaxis used or with organ dysfunction as a result of previous transplantation. Effective T-cell depletion with adequate post transplant immunosuppression would be the best preventive measure to avoid severe GVHD in HHCT; otherwise, incorporating prednisolone into GVHD prophylaxis deserves consideration according to Ogawa and Storb et al. 18, 19 The impact of HLA disparity on GVHD and TRM in HHCT could not be evaluated statistically in this study because of a small number of patients. Huo et al. 20 reported that HLA-B mismatch was associated with a higher risk of acute GVHD and TRM in unmanipulated HHCT. The effect of HLA disparity on outcomes after T-cell-depleted HHCT is required to be evaluated considering other variables such as a T-cell dose and post transplant immune suppression.
In our patients with initial HHCT, we preferred to replace the initial parental donor with another donor, as residual T cells of host origin were assumed to recognize major histocompatibility antigens of the donor and cause second graft rejection. 21 Guardiola et al. 13 concluded that the use of a different donor had no significant influence on the outcome. However, in patients with residual T-cell-mediated host immunity, many studies show that the use of a different donor may be beneficial. 7, 22, 23 It has been shown that CD3 þ /CD8 þ cells frequently emerge in graft rejection, 24, 25 and anti-HLA donor-specific antibodies have been reported to be associated with GF in matched or mismatched transplantation. 5, 26, 27 One of the biggest problems with second transplantation is high TRM, and infection is the most frequent cause of death. 5, 13 Most patients have poor performance status, organ toxicities and preexisting infection because of prolonged cytopenia at second transplantation. In addition, overlapping regimen-related toxicity and immune suppression because of the second conditioning chemotherapy can in no way be negligible factors. Therefore, safe and effective conditioning and rapid engraftment and immune recovery could be key factors for successful second transplantation. In the setting of second HCT for GF, the purpose of preparative regimens is immunoablation in order to secure stem cell engraftment. We used fludarabine and CY-based preparative regimen, with or without ATG and TBI. Fludarabine suppresses host immunocompetent T and NK cells that are involved in graft rejection. 28, 29 Neutrophil engraftment is also enhanced under preparative regimens with alkylating agents including melphalan, BU and CY, 5 and low-dose TBI. 23, 30, 31 ATG also has immunosuppressive effect and reduces the risk of GVHD. 28, 31 In this study, only two patients received additional ATG in second transplantation, because all patients were conditioned with ATG in first transplantation, and intervals between two transplantations were short. This study suggested that fludarabine and CY-based RIC after short interval from first transplantation enabled successful donor-cell engraftment with limited toxicity.
According to the data of salvage UCBT, multiple infections were encountered and these tended to be protracted. 5, 16 The fact that day 100 TRM amounted to 50%, mostly related to infectious complications, it illustrates the importance of immune reconstitution after transplant. 5, 32 Compared with HLA-matched unrelated PBSCT, reconstitution of CD3 þ T cells, naive and memory CD4 þ T cells, and CD8 þ T cells is significantly delayed in UCBT. 33 Delayed T-cell recovery appears to be associated with an increased risk of viral and bacterial infections in the first 100 days. 33, 34 Immune recovery in our patients; the median numbers of CD3 þ cells, CD4 þ cells and CD56 þ NK cells at 3 months post transplant were 530, 108 and 425 cells/mL, respectively. Immune reconstitution showed more rapid recovery compared with UCBTor CD34 þ -selected HHCT, 33, 35 and these results were comparable with those of HLA-matched unrelated PBSCT. 33 Patients undergoing unmanipulated HCT have o1% risk of developing EBV-associated PTLD, whereas, T-cell depleted HCT is associated with a high risk of PTLD (71%). The risk factors for PTLD were old age, T-cell depletion of the graft, underlying immune deficiency, ATG use and unrelated or HLA-mismatched grafts. 36, 37 In our study, six of the patients developed EBV DNAemia, despite long-term antiviral prophylaxis with Intravenous immunoglobulin. We used rituximab for in vivo B-cell depletion to reduce the risk of PTLD for the patients receiving CD3-depleted grafts, and there were no fatal viral infection after rituximab therapy.
CMV infection, also, has been a great threat to the survival of the patients. CMV frequently reactivates in the post transplant period and can lead to life threatening invasive CMV disease. GF and second transplantation after prolonged neutropenia and immune deficiency are at high risk for CMV reactivation. To reduce CMVassociated complications, we adopted an intensive prophylactic strategy consisting of ganciclovir and foscarnet, biweekly CMV monitoring and pre-emptive therapy with ganciclovir. The use of intensive CMV and EBV prevention strategies might have been responsible for the decreased incidence of significant CMV and EBV disease. Also, it is possible that rapid immune reconstitution after transplant contributed to these satisfactory results.
In conclusion, we showed that T-cell-depleted haploidentical PBSCT under fludarabine and CY-based RIC with aggressive infectious prophylaxis allowed rapid engraftment and immune recovery after second transplantation with low toxicities, which translate to favorable outcome. Although this is a retrospective study consisting of small numbers of patients and the follow-up period was short for some patients, our experience demonstrated that second HHCT is a viable option in the management of primary GF, and it should be considered early.
